FDA Committee Recommends Infliximab Biosimilar

FDA Committee Recommends Infliximab Biosimilar

Celltrion is seeking approval of CT-P13 for the treatment of a variety of autoimmune diseases, including Crohn's disease, ulcerative colitis, and rheumatoid arthritis. If approved by FDA, Pfizer would assume commercialization rights for the medication

(Visited 3 times, 1 visits today)
2
Like
Save

Comments

Comments are disabled for this post.